Business / Finance

RSS

Ranir acquires Oralys Dental

Building on its position as a global leader in private label consumer oral and personal health care products, Ranir, today announced it has acquired Oralys Dental, the leading provider of private label toothbrushes in France.

10 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

Stradis Healthcare signs definitive agreement to acquire Medikmark

Stradis Healthcare is pleased to announce that it has entered into a definitive acquisition agreement with Medikmark, a leading provider of healthcare kits based in Waukegan, IL, under which Stradis will acquire all shares of Medikmark.

7 Nov 2014

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.

6 Nov 2014

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates.

6 Nov 2014

Perrigo agrees to acquire Omega for $4.5 billion

Perrigo Company plc, a leading global provider of "Quality Affordable Healthcare Products," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for €3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for €2.48 billion and the assumption of €1.1 billion in debt.

6 Nov 2014

Cardio3 BioSciences announces acquisition of CorQuest Medical

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery.

5 Nov 2014

Gentiva Health Services reports revenues of $498.0 million for Q3 2014

Gentiva Health Services, Inc., one of the largest providers of home health, hospice and community care services in the United States, today reported net revenues of $498.0 million, adjusted EBITDA of $48.5 million and adjusted income attributable to Gentiva shareholders per diluted share of $0.28.

5 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014

Abide, Oxford partner to explore therapeutic potential of serine hydrolases

Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.

5 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014.

4 Nov 2014

Sigma-Aldrich acquires Cell Marque

Sigma-Aldrich Corporation, a leading Life Science and High Technology company, announced it has completed its acquisition of Rocklin, California based Cell Marque Corporation, an industry-leading provider of in vitro diagnostic (IVD) antibody reagents and kits. The Company expects this acquisition to be neutral to mildly accretive to earnings per share in 2015. Terms of the transaction were not disclosed.

4 Nov 2014

CVS Health's net revenues increase 9.7% to $35.0B in third quarter 2014

CVS Health Corporation today announced operating results for the three months ended September 30, 2014.

4 Nov 2014

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

4 Nov 2014

Bio-Techne to acquire CyVek for $60M

Bio-Techne Corporation announced today that it has agreed to acquire CyVek, Inc. (CyVek) for $60 million in cash, plus a potential earn-out payment of up to $35 million based on CyVek revenue over the 30-month period following the closing and an additional potential earn-out payment based on CyVek revenue through 2020 in excess of $100 million.

4 Nov 2014

Triple-S Management announces $50M stock repurchase program, reports consolidated revenues of $567.2M

Triple-S Management Corporation (NYSE: GTS), one of the leading managed care companies in Puerto Rico, today announced consolidated revenues of $567.2 million and consolidated operating income of $8.9 million for the three months ended September 30, 2014.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

NeuroDerm launches initial public offering of 4,500,000 shares

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).

3 Nov 2014

Business / Finance

Ranir acquires Oralys Dental

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Johnson & Johnson completes acquisition of Alios BioPharma

Stradis Healthcare signs definitive agreement to acquire Medikmark

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Perrigo agrees to acquire Omega for $4.5 billion

Cardio3 BioSciences announces acquisition of CorQuest Medical

Gentiva Health Services reports revenues of $498.0 million for Q3 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

Abide, Oxford partner to explore therapeutic potential of serine hydrolases

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Sigma-Aldrich acquires Cell Marque

CVS Health's net revenues increase 9.7% to $35.0B in third quarter 2014

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Bio-Techne to acquire CyVek for $60M

Triple-S Management announces $50M stock repurchase program, reports consolidated revenues of $567.2M

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

NeuroDerm launches initial public offering of 4,500,000 shares

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News